HomeALNOV • EPA
add
Novacyt SA
Previous close
€0.58
Day range
€0.56 - €0.60
Year range
€0.49 - €1.59
Market cap
40.05M EUR
Avg Volume
304.32K
P/E ratio
-
Dividend yield
-
Primary exchange
EPA
Market news
Financials
Income Statement
Revenue
Net income
(GBP) | Jun 2024info | Y/Y change |
---|---|---|
Revenue | 5.16M | 209.13% |
Operating expense | 7.92M | 92.89% |
Net income | -8.85M | -112.01% |
Net profit margin | -171.47 | 31.41% |
Earnings per share | — | — |
EBITDA | -12.02M | -324.07% |
Effective tax rate | 1.22% | — |
Balance Sheet
Total assets
Total liabilities
(GBP) | Jun 2024info | Y/Y change |
---|---|---|
Cash and short-term investments | 32.95M | -59.69% |
Total assets | 99.40M | -24.78% |
Total liabilities | 28.99M | 16.70% |
Total equity | 70.41M | — |
Shares outstanding | 70.63M | — |
Price to book | 0.58 | — |
Return on assets | -36.30% | — |
Return on capital | -43.18% | — |
Cash Flow
Net change in cash
(GBP) | Jun 2024info | Y/Y change |
---|---|---|
Net income | -8.85M | -112.01% |
Cash from operations | -4.54M | -59.67% |
Cash from investing | -566.50K | -212.18% |
Cash from financing | -430.50K | -61.24% |
Net change in cash | -5.56M | -112.16% |
Free cash flow | -17.73M | -943.16% |
About
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
Founded
2006
Website
Employees
240